Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
CA 2484182 A1 · Owner: Genpat77 Pharmacogenetics Ag · Inventors: Utku, Nalan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Bispecific molecules characterized by having at least a first binding domain which binds T-cell immune response cDNA 7 (TIRC7) and a second binding domain which binds T cell receptor (TCR), in particular TCR beta or gamma chain; compositions comprising said bispecific molecules and their use for the diagnosis and the treatment of diseases related to a disorder of the immune response.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 29, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 29, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 29, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.